Strydaflex is an intra-articular injectable specifically formulated for joints. Proteomics and cytokine characterizations show consistency in every dose, with components demonstrated to play a role in both tissue healing and the anti-inflammatory cascade. 

The Hilltop Bio Difference

Compared to older orthobiologics like PRP or stem cells that are variable, labor-intensive, and require special equipment, our therapies are consistent dose-to-dose and are ready to use in under a minute, with no processing, no thawing, and no equipment!

One-Step Prep: Ready to use in under a minute

No Variability: Consistent formulation delivers reliable results

100% Natural: Avoid risks associated with pharmaceuticals or steroids

Save Time & Money: no equipment or processing required

Off-the-Shelf: Long-term, room temperature storage

Quality: Manufactured under strict cGMP/cGTP guidelines

How Does Strydaflex Work?

Strydaflex contains a proprietary mix of cytokines, growth factors and exosomes— factors with a demonstrated ability to stimulate a cell-signaling cascade to reduce inflammation and promote healing. Strydaflex has been formulated to contain factors most important for joint homeostasis, including those that decrease the destructive effects of pro-inflammatory cytokines and others that have demonstrated beneficial effects in mitigating the clinical signs associated with joint disease and/or injury.

Studies

The summary of our Strydaflex Safety Study is available here. The full study will be published this fall. 

References:

  1. Dinarello CA. Historical review of cytokines. Eur J Immunol 2007;37(Suppl1):S35-S45.
  2. Gelhorn A and Han A. The use of dehydrated human amnion/chorion membrane allograft injection for the treatment of tendinopathy or arthritis: A case series involving 40 patients. P M & R 2017;9:1236-1243.
  3. Gulati K, Guhathakurta S, Joshi J, et al. Cytokines and their role in health and disease: a brief overview. MOJ Immunol 2016;4(2):00121.
  4. Gupta A. Allogenic Amniotic Tissue for Treatment of Knee and Hip Osteoarthritis. Pharmaceuticals (Basel). 2022 Mar 26;15(4):404.
  5. Kimmerling, K.A., Gomoll, A.H., Farr, J. et al. Amniotic suspension allograft improves pain and function in a rat meniscal tear-induced osteoarthritis model. Arthritis Res Ther 24, 63 (2022).
  6. Shimberg, M. The use of amniotic-fluid concentrate in orthopedic conditions. Journal of Bone and Joint Surgery, Vol. 20 No. 1, January 1938. 
  7. Williams, K. B., & Ehrhart, N. P. Regenerative medicine 2.0: extracellular vesicle–based therapeutics for musculoskeletal tissue regeneration. JAVMA, 2022; 260(7), 683-689.